îæ€çŽ¢
îæ€çŽ¢
î
Korro Bio Inc
KRROîãŠã©ãããªã¹ãã«è¿œå
13.810USD
+0.750+5.74%
çµå€Â 09-11 16:00ïŒETïŒ
203.67Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现æ å ± Korro Bio Inc äŒæ¥å
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc ãããã£ãŒã«
îäŒæ¥ã³ãŒãKRRO
äŒç€ŸåKorro Bio Inc
äžå Žæ¥Oct 03, 2019
æé«çµå¶è²¬ä»»è
ãCEOãDr. Ram Aiyar, Ph.D.
åŸæ¥å¡æ°104
蚌åžçš®é¡Ordinary Share
決ç®ææ«Oct 03
æ¬ç€Ÿæåšå°One Kendall Square. Building 600-700
éœåžCAMBRIDGE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·02139
é»è©±çªå·16174681999
ãŠã§ããµã€ãhttps://www.korrobio.com/
äŒæ¥ã³ãŒãKRRO
äžå Žæ¥Oct 03, 2019
æé«çµå¶è²¬ä»»è
ãCEOãDr. Ram Aiyar, Ph.D.
Korro Bio Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
23.60K
+23.31%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
ãããã質å
Korro Bio Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îKorro Bio Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ããDr. Nessan Bermingham, Ph.D.
Korro Bio IncïŒKRROïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2026Q1æç¹ã§ãKorro Bio Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯215瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ11.84Mã§ãå
šäœã®86.30%ãå ããŠããŸãã2025Q4ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯782639.00å¢å ããŠããŸãã